Compile Data Set for Download or QSAR
Report error Found 667 of affinity data for UniProtKB/TrEMBL: Q5XXA6
TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM469657(US20200361871A1, Example 1 | N-tert-Butyl-4-[[2-(2...)
Affinity DataEC50:  210nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM469658(US20200361871A1, Example 1.1 | N-(1,1-Dimethylprop...)
Affinity DataEC50:  560nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM469669(US20200361871A1, Example 1.2 | US11364246, Example...)
Affinity DataEC50:  540nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509135(US20200361871A1, Example 1.3 | US11364246, Example...)
Affinity DataEC50:  240nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509159(US20200361871A1, Example 1.4 | US11364246, Example...)
Affinity DataEC50:  400nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509225(US20200361871A1, Example 1.5 | US11364246, Example...)
Affinity DataEC50:  340nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509226(US20200361871A1, Example 1.6 | 4-[[2-(5-Chloro-2-h...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509228(US20200361871A1, Example 1.7 | US11364246, Example...)
Affinity DataEC50:  150nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509229(US20200361871A1, Example 1.8 | US11364246, Example...)
Affinity DataEC50:  410nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509230(US20200361871A1, Example 1.9 | US11364246, Example...)
Affinity DataEC50:  4.20E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509231(US20200361871A1, Example 1.10 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  80nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509232(US20200361871A1, Example 2 | N-tert-Butyl-3-[[2-(5...)
Affinity DataEC50:  270nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509233(US20200361871A1, Example 2.1 | US11364246, Example...)
Affinity DataEC50:  490nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509234(US20200361871A1, Example 2.2 | US11364246, Example...)
Affinity DataEC50:  1.61E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509235(US20200361871A1, Example 2.3 | US11364246, Example...)
Affinity DataEC50:  590nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509238(US20200361871A1, Example 2.5 | US11364246, Example...)
Affinity DataEC50:  1.34E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509562(US20200361871A1, Example 2.6 | US11364246, Example...)
Affinity DataEC50:  2.91E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509563(US20200361871A1, Example 2.7 | US11364246, Example...)
Affinity DataEC50:  8.19E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509564(US20200361871A1, Example 2.8 | US11364246, Example...)
Affinity DataEC50:  4.55E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509565(US20200361871A1, Example 2.9 | US11364246, Example...)
Affinity DataEC50:  990nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509566(US20200361871A1, Example 2.10 | US11364246, Exampl...)
Affinity DataEC50:  460nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509567(US20200361871A1, Example 2.11 | US11364246, Exampl...)
Affinity DataEC50:  430nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509568(US20200361871A1, Example 2.12 | US11364246, Exampl...)
Affinity DataEC50:  310nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509569(US20200361871A1, Example 2.13 | US11364246, Exampl...)
Affinity DataEC50:  460nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509570(US20200361871A1, Example 2.14 | US11364246, Exampl...)
Affinity DataEC50:  1.78E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509571(US20200361871A1, Example 2.15 | US11364246, Exampl...)
Affinity DataEC50:  490nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509572(US20200361871A1, Example 2.16 | US11364246, Exampl...)
Affinity DataEC50:  4.27E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509573(US20200361871A1, Example 2.17 | US11364246, Exampl...)
Affinity DataEC50:  270nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509574(US20200361871A1, Example 2.18 | US11364246, Exampl...)
Affinity DataEC50:  1.41E+3nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509575(US20200361871A1, Example 2.19 | US11364246, Exampl...)
Affinity DataEC50:  460nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509576(US20200361871A1, Example 3 | N-tert-Butyl-4-[[2-(5...)
Affinity DataEC50:  110nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509577(US20200361871A1, Example 3.1a | US11364246, Exampl...)
Affinity DataEC50:  180nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509578(US20200361871A1, Example 3.2a | US11364246, Exampl...)
Affinity DataEC50:  160nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509579(US20200361871A1, Example 3.3a | US11364246, Exampl...)
Affinity DataEC50:  70nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509580(US20200361871A1, Example 3.4a | US11364246, Exampl...)
Affinity DataEC50:  140nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509581(US20200361871A1, Example 3.5a | US11364246, Exampl...)
Affinity DataEC50:  500nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509583(US20200361871A1, Example 3.6a | US11364246, Exampl...)
Affinity DataEC50:  370nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509584(US20200361871A1, Example 3.7a | US11364246, Exampl...)
Affinity DataEC50:  280nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509585(US20200361871A1, Example 3.5b | N-tert-Butyl-4-[[2...)
Affinity DataEC50:  200nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509586(US20200361871A1, Example 3.6b | US11364246, Exampl...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509587(US20200361871A1, Example 3.7b | US11364246, Exampl...)
Affinity DataEC50:  180nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509588(US20200361871A1, Example 3.8b | US11364246, Exampl...)
Affinity DataEC50:  300nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509589(US20200361871A1, Example 3.9b | US11364246, Exampl...)
Affinity DataEC50:  960nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509590(US20200361871A1, Example 3.10b | US11364246, Examp...)
Affinity DataEC50:  460nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509591(US20200361871A1, Example 3.11b | US11364246, Examp...)
Affinity DataEC50:  410nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509592(US20200361871A1, Example 3.12b | US11364246, Examp...)
Affinity DataEC50:  340nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509593(US20200361871A1, Example 3.13b | US11364246, Examp...)
Affinity DataEC50:  250nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509594(US20200361871A1, Example 3.14b | US11364246, Examp...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509595(US20200361871A1, Example 3.16b | US11364246, Examp...)
Affinity DataEC50:  170nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetAnoctamin-1(Human)
Enterprise Therapeutics

US Patent
LigandPNGBDBM509596(US20200361871A1, Example 3.17b | US11364246, Examp...)
Affinity DataEC50:  120nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 667 total ) | Next | Last >>
Jump to: